AXS Stock Recent News
AXS LATEST HEADLINES
AXS, QFIN, and PINE made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 11, 2024.
QFIN, AXS, and MITSY made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 11, 2024.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DEC, AXS, and MITSY made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 9, 2024.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Does Axis Capital (AXS) have what it takes to be a top stock pick for momentum investors? Let's find out.
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company's New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Axis Capital (AXS) and Mr Cooper (COOP) have performed compared to their sector so far this year.
Axis Capital (AXS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.